CEACAM5 and neoplasm: Recent data from a phase I trial (NCT05396300) evaluated a CEA-CAR-T cell therapeutic agent designed to activate only under hypoxic conditions [96], thereby restricting cell activity primarily to tumor areas while sparing healthy tissues.